Education
About Us
Working with TipRanks
Follow Us
Certara (CERT)
NASDAQ:CERT
CERT Stock Chart & Stats
$8.64
-$0.37(-3.29%)
At close: 4:00 PM EST
$8.64
-$0.37(-3.29%)
Day’s Range― - ―
52-Week Range$8.03 - $15.69
Previous CloseN/A
Volume176.64K
Average Volume (3M)2.26M
Market Cap
$1.32B
Enterprise Value$2.10B
Total Cash (Recent Filing)$172.71M
Total Debt (Recent Filing)$302.51M
Price to Earnings (P/E)119.1
Beta1.53
Next Earnings
Feb 26, 2026EPS Estimate
0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.14
Shares Outstanding159,273,360
10 Day Avg. Volume3,670,517
30 Day Avg. Volume2,258,675
Financial Highlights & Ratios
PEG Ratio1.80
Price to Book (P/B)1.61
Price to Sales (P/S)4.44
P/FCF Ratio21.67
Enterprise Value/Market Cap1.59
Enterprise Value/Revenue5.05
Enterprise Value/Gross Profit8.69
Enterprise Value/Ebitda19.67
Forecast
1Y Price Target
$13.25Price Target Upside53.36% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
EPS Forecast (FY)0.45
Revenue Forecast (FY)$418.45M
Bulls Say, Bears Say
Bulls Say
Financial PerformanceAdjusted EBITDA came in 10% ahead of the model and consensus, with Certara’s adjusted EBITDA margin significantly exceeding estimates.
Innovation And GrowthNew AI-powered launches are expected to drive increased adoption as Certara enters its next-gen AI and cloud era.
Market LeadershipCertara is a leader in the fast-growing and under-penetrated biosimulation market, helping pharmaceutical companies improve the efficiency of their drug development processes.
Bears Say
Customer SpendingServices bookings were negatively impacted by cautious spending behavior among tier-1 customers, which has continued into the fourth quarter.
Market ConditionsManagement characterized the end-market as subdued, especially compared to the high funding environment during the pandemic.
Revenue GuidanceCertara lowered the midpoint of its 2025 revenue guide due to softer services bookings in the third quarter.
Certara News
CERT FAQ
What was Certara’s price range in the past 12 months?
Certara lowest stock price was $8.03 and its highest was $15.69 in the past 12 months.
What is Certara’s market cap?
Certara’s market cap is $1.32B.
When is Certara’s upcoming earnings report date?
Certara’s upcoming earnings report date is Feb 26, 2026 which is in 95 days.
How were Certara’s earnings last quarter?
Certara released its earnings results on Nov 06, 2025. The company reported $0.14 earnings per share for the quarter, beating the consensus estimate of $0.114 by $0.026.
Is Certara overvalued?
According to Wall Street analysts Certara’s price is currently Undervalued.
Does Certara pay dividends?
Certara does not currently pay dividends.
What is Certara’s EPS estimate?
Certara’s EPS estimate is 0.11.
How many shares outstanding does Certara have?
Certara has 159,273,360 shares outstanding.
What happened to Certara’s price movement after its last earnings report?
Certara reported an EPS of $0.14 in its last earnings report, beating expectations of $0.114. Following the earnings report the stock price went down -23.07%.
Which hedge fund is a major shareholder of Certara?
Currently, no hedge funds are holding shares in CERT
Certara Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$13.25 (53.36% Upside)
$13.25 (53.36% Upside)
Blogger Sentiment
Bullish
CERT Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 3.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $200.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 1.4%
Last 30 Days ▼ 1.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-15.91%
12-Months-Change
Fundamentals
Return on Equity
1.03%
Trailing 12-Months
Asset Growth
-0.48%
Trailing 12-Months
Company Description
Certara
Certara, Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, and market access. Further, company offers software, comprising mechanistic biosimulation platform, empirical PK/PD biosimulation platform, data standardization and compliance software, scientific informatics platform, clinical outcomes databases for biosimulation, authoring and management of regulatory submissions platform, and market access communication platform. The company serves biopharmaceutical companies, and academic and government institutions. It has operations in the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, Australia, and China. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
CERT Company Deck
CERT Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Certara reported strong growth in its software segment and increased R&D investment, alongside successful product launches and progress in the Chemaxon acquisition. However, there were noticeable challenges in the services segment and slower bookings growth, driven by cautious spending among Tier 1 customers. The balance of positive and negative elements suggests a mixed environment.View all CERT earnings summariesCERT Stock 12 Month Forecast
Average Price Target
$13.25
▲(53.36% Upside)
Technical Analysis
Omnicell
―
Health Catalyst
―
Schrodinger
―
SOPHiA GENETICS
―
Definitive Healthcare Corp
―
Ownership Overview
2.28% Insiders
27.74% Mutual Funds
34.18% Other Institutional Investors
18.89% Public Companies and
Individual Investors